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Abstract
Influenza virus evades host immunity through antigenic drift and shift, and continues to circulate in the human population
causing periodic outbreaks including the recent 2009 pandemic. A large segment of the population was potentially
susceptible to this novel strain of virus. Historically, monoclonal antibodies (MAbs) have been fundamental tools for
diagnosis and epitope mapping of influenza viruses and their importance as an alternate treatment option is also being
realized. The current study describes isolation of a high affinity (KD = 2.160.4 pM) murine MAb, MA2077 that binds
specifically to the hemagglutinin (HA) surface glycoprotein of the pandemic virus. The antibody neutralized the 2009
pandemic H1N1 virus in an in vitro microneutralization assay (IC50 = 0.08 mg/ml). MA2077 also showed hemagglutination
inhibition activity (HI titre of 0.50 mg/ml) against the pandemic virus. In a competition ELISA, MA2077 competed with the
binding site of the human MAb, 2D1 (isolated from a survivor of the 1918 Spanish flu pandemic) on pandemic H1N1 HA.
Epitope mapping studies using yeast cell-surface display of a stable HA1 fragment, wherein ‘Sa’ and ‘Sb’ sites were
independently mutated, localized the binding site of MA2077 within the ‘Sa’ antigenic site. These studies will facilitate our
understanding of antigen antibody interaction in the context of neutralization of the pandemic influenza virus.
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Introduction
The 2009 H1N1 swine origin influenza A virus (S-OIV,
hereafter referred to as pandemic H1N1) is a novel reassortant
strain of influenza virus which has gene segments originating from
swine, avian and human influenza A viruses and is immunolog-
ically distinct from the seasonal H1N1 strains circulating before
2009 [1]. Till date, pandemic H1N1 has caused more than 1.4
million infections with about 25,000 deaths worldwide [2].
Annually updated seasonal tri-valent vaccine is the major
prophylactic treatment option for influenza virus infection.
However, seasonal influenza vaccines used before 2009, produce
low or no cross-reactive antibodies against pandemic H1N1.
Moreover, it has been observed that persons below the age of 30
had low cross-reactive antibody titers against pandemic H1N1 [3].
Antiviral drugs such as, oseltamivir are the sole therapeutic option
for treating pandemic H1N1 infection. In addition, rapid diagnosis
establishing the causative agent and identification of strain is
crucial in a pandemic scenario. Owing to the novelty of this 2009
H1N1 S-OIV and susceptibility of large population, it is
imperative to seek alternate diagnostic and treatment modalities.
Neutralizing antibodies against the major surface glycoprotein
of the influenza virus, hemagglutinin (HA), is the primary correlate
of protection in humans [4]. Four major antigenic sites have been
mapped onto the H1 HA and antibodies to each of which can
neutralize the infectivity of the virus. Two immunodominant sites
(Sa and Sb) are located proximal to the receptor binding pocket
and elicit high potency neutralizing antibodies. The other two
antigenic sites (Ca and Cb) are located at the subunit interface and
esterase domain, respectively [5–7]. The H1N1 virus caused a
deadly pandemic in 1918 (Spanish flu), killing 20–40 million
people worldwide [8]. Though the descendants of this 1918
influenza H1 strains have been circulating in humans, they have
antigenically diverged from the 1918 virus, including at the four
major antigenic sites. Interestingly, 1918 and 2009 H1N1 viruses
share a nearly identical ‘Sa’ antigenic site on HA [9,10].
Specific high affinity antibodies that will enable sensitive
detection of the 2009 pandemic H1N1 virus, differentiating it
from other seasonal H1N1 strains, are useful. Moreover,
antibodies neutralizing pandemic H1N1 can be useful for passive
therapeutic purposes. In this direction, we report here the isolation
of a novel, high affinity neutralizing mouse monoclonal antibody
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(MAb) against the 2009 pandemic H1N1-virus. The epitope of this
MAb has been mapped onto the ‘Sa’ antigenic site.
Materials and Methods
Cell lines, antigens and virus
Madine Darby Canine Kidney (MDCK) cell line (CCL-34) was
obtained from American Type Culture Collection, Manassas, VA,
USA and cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Sigma Aldrich Inc., St. Louis, MO, USA). Sp2/O
mouse myeloma cell line was obtained from National Centre for
Cell Science, Pune, India and cultured in RPMI-1640 medium
(Sigma Aldrich Inc.). Media were supplemented with 10% fetal
bovine serum (FBS) and an antibiotic-antimycotic cocktail
[Penicillin (100 units/ml), Streptomycin (100 mg/ml) and Ampho-
tericin B (0.25 mg/ml); Biological Industries, Kibbutz beit,
Haemek, Israel]. Both cell lines were cultured at 37uC under
humidified conditions with 5% CO2.
Pandemic H1N1 NYMCX-179A (A/California/07/2009: In-
fluenza virus infectious NYMCX-179A, NIBSC Code 09/124)
and seasonal H1N1 (A/Solomon Islands/03/2006: Influenza virus
infectious IVR-145, NIBSC code 07/144) were received from
NIBSC, UK and passaged in MDCK cells in presence of TPCK-
trypsin (2 mg/ml; Sigma Aldrich Inc.). Titer of the virus stock was
calculated using Reed and Muench method [11].
Generation of monoclonal antibodies (MAbs)
Female BALB/cJ mice (8–10 weeks old, Small Animal
Experimental Facility, National Institute of Immunology, New
Delhi, India) were immunized subcutaneously with 7.5 mg
equivalent of HA of inactivated, alum adsorbed strain of H1N1
(A/California/07/2009) (Serum Institute of India Limited, Pune,
India). Animals were boosted intraperitoneally two times at 4 week
intervals with the same amount of the antigen. The animals were
kept in the conventional containment conditions and fed ad libitum.
Immunized animals were used to generate MAbs as per the
protocol described elsewhere [12]. In brief, 4–6 weeks after the
second booster, the mouse showing highest antibody titres against
inactivated pandemic H1N1 antigen in ELISA, was administered
intraperitoneally 2 boosters, 7.5 mg equivalent of HA of pandemic
H1N1, on consecutive days. On the 4th day, the mouse was
euthanized by administration of ketamine-HCl (75 mg/kg) and
spleen was harvested aseptically. Splenocytes (126106) thus
obtained were fused with Sp2/O myeloma cells in 2:1 ratio using
50% polyethylene glycol (Sigma Aldrich Inc.) and plated in eight
24-well cell culture plates (Greiner Bio-one, GmbH, Frickenhau-
sen, Germany) seeded with peritoneal macrophages (105/well) on
the previous day. The hybrid cells were selected by growing the
fused cells in HAT selection medium (Sigma Aldrich Inc.). Hybrid
cell clones secreting MAbs reacting with pandemic H1N1 were
identified by screening culture supernatants in ELISA as described
later in this section and single cell clones were obtained by 2–3
rounds of limiting dilution. Specific hybrid cell clone secreting
MAb neutralizing pandemic H1N1 virus was grown as ascites in
BALB/cJ mice primed with Pristane (2, 6, 10, 14 – tetramethyl-
pentadecane, Sigma Aldrich Inc.). The antibody was purified from
ascites using Protein-G Sepharose (GE Healthcare Biosciences AB,
Uppsala, Sweden) as per the manufacturer’s instructions. Isotyping
of the antibodies was carried out using murine MAb isotyping kit
(Sigma Aldrich Inc.) by indirect ELISA as per the instructions
provided with the kit.
Ethics statement
All the experiments were performed after due approval from
Institutional Animal Ethical Committee, National Institute of
Immunology, New Delhi (IAEC#247/10) and following its
guidelines.
ELISA reactivity studies
Briefly, 96-well plates (Greiner Bio-one) were coated with beta-
propiolactone (BPL)- inactivated pandemic H1N1 virus (A/
California/07/2009) (Serum Institute of India Limited) (200 ng/
well) and Vaxigrip [2009–10 season, Sanofi Pasteur SA, Val de
reuil, France (comprising of H1N1 A/Brisbane/59/2007, H3N2
A/Brisbane/10/2007 and B/Brisbane/60/2008)] (equivalent to
200 ng total HA protein per well). Microtiter plates coated with
ovalbumin (200 ng/well) were used as negative control. In
addition, mammalian-expressed recombinant HA (rHA) protein
of pandemic H1N1 (A/California/04/2009) and rHA of seasonal
H1N1 (A/Solomon Islands/03/2006) (160 ng/well; Sino Biolog-
ical Inc., Beijing, China) were also immobilized. Coating was
performed at 37uC for 1 h followed by overnight incubation at
4uC. Following day, plates were blocked with 1% BSA or 1% milk
protein in phosphate buffer saline (PBS) (pH 7.4) for 2 h at 37uC.
After washing the plates with PBS containing 0.05% Tween-20
(PBST), 100 ml of cell culture supernatants or purified MAb
MA2077 at varying concentration (10 mg/ml to 0.1 ng/ml) were
added and plates were incubated for 1 h at 37uC. After 3 rounds of
washing with PBST, HRP conjugated goat-anti-mouse antibody
(Pierce Biotechnology Inc., Rockford, IL, USA) was added at
1:10000 dilution and incubated for 1 h at 37uC. Following 3
washes with PBST, the reaction was developed using 0.5 mg/ml
o-phenylene-diamine (OPD) (Sigma Aldrich Inc.) as substrate
along with 0.06% hydrogen peroxide (Merck, Mumbai, India) in
0.1M citrate-phosphate buffer (pH 5). The reaction was stopped
with 50 ml 5N H2SO4 and optical density was measured at
490 nm with a reference wavelength of 630 nm.
Binding affinity studies using Surface Plasmon Resonance
(SPR)
The binding affinity of MAb MA2077 to rHA of pandemic
H1N1 A/California/04/2009 (Sino Biological Inc.) was deter-
mined by Surface Plasmon Resonance (SPR) experiments
performed with a Biacore 2000 optical biosensor (Biacore,
Uppsala, Sweden) at 25uC. Eight hundred resonance units (RU)
of MA2077 was immobilized by standard amine coupling to the
surface of a research-grade CM5 chip (GE HealthCare, Uppsala,
Sweden). A sensor channel immobilized with ovalbumin served as
a negative control for each binding interaction. Five different
concentrations of the pandemic H1N1 A/California/04/2009
rHA or H1N1 A/PR/8/34 rHA trimer (Sino Biological Inc) in the
range between 0.75–5.5 nM were passed over each channel in a
running buffer of PBS (pH 7.4) containing 0.05% P20 surfactant.
Both binding and dissociation were measured at a flow rate of
30 ml/min. After every binding event, the sensor surface was
regenerated by repeated washes with 4M MgCl2 at a flow rate of
100 ml/min. Each binding curve was analyzed after correcting for
non-specific binding by subtraction of the signals obtained from
the negative-control flow channel. The kinetic parameters were
obtained by fitting the data to the simple 1:1 Langmuir interaction
model using BIA EVALUATION 3.1 software.
Microneutralization assay
Microneutralization assay was performed using MDCK cell line
as per the WHO guidelines [13]. MDCK cells (15000/well) were
Neutralizing Antibody against Pandemic H1N1 Virus
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seeded in 96-well cell culture plate (Greiner Bio-one) and
incubated overnight under standard culture conditions. The next
day, an equal volume of antibody and 100 TCID50 units of the
virus were incubated for 1 h at room temperature. After 1 h, virus-
antibody mixture was added onto the seeded MDCK cells and
plates were further incubated for 24 h at 32uC under humidified
atmosphere and 5% CO2. Subsequently, cells were fixed with 80%
acetone and probed with 1:4000 dilution of anti-influenza A–
nucleoprotein antibody (Millipore, Billerica, MA, USA). After 3
rounds of washing with PBST, the plates were incubated with
1:10000 dilution of HRP conjugated goat-anti-mouse antibody
(Pierce Biotechnology Inc.) and incubated for 1 h at 37uC. After
washing three times with PBST, reaction was developed as
mentioned above for ELISA. The fifty percent inhibitory
concentration (IC50) of the neutralizing antibody was calculated
using the non-linear regression program of GraphPad Prism
software. The specific neutralizing activity of the MAb was
calculated as the lowest concentration of the antibody that showed
10% neutralization of 100 TCID50 units of the virus.
Hemagglutination inhibition (HI) assay
HI assay was performed according to the WHO guidelines
using four HA units of the influenza virus and 1% guinea pig
RBCs [13]. The specific HI activity (HI titre) of the MAb
represents the lowest concentration of the antibody showing HI
activity.
Epitope mapping
i) Competition ELISA. Competition ELISA was carried out
as described elsewhere [14]. Briefly, 96-well half area plates
(Corning Incorporated, NY, USA) were coated with 125 ng of
pandemic H1N1 A/California/04/2009 rHA in PBS, overnight at
4uC. Plates were then washed 3 times with PBST and blocked for
1 h with 200 ml of 1% BSA in PBST. After washing, 25 ml of MAb
2D1 was added to each well at 2 mg/ml concentration followed by
a 4-fold serial dilution. After 2 h of incubation with 2D1, the
solution in each well was replaced by 25 ml of MA2077 at a fixed
concentration (1 ng/ml) as determined from the titration curve of
MA2077 with pandemic H1N1 rHA. The experiment was carried
out in quadruplicates. After 2 h of incubation with MA2077, the
plates were washed with PBST. The wells were then probed with
appropriate secondary antibodies. Two sets of wells were probed
with 25 ml of alkaline phosphatase (ALP)-conjugated goat anti-
mouse antibody (Sigma Aldrich Inc.) at a predetermined dilution
(1:10000) and incubated at room temperature for 2 h. Alterna-
tively, the other two sets of wells were probed with 25 ml of ALP-
conjugated goat anti-human antibody (Sigma Aldrich Inc.) at a
predetermined dilution (1:10000). The plates were washed and
developed using the chromogenic substrate p-nitrophenyl phos-
phate (Sigma Aldrich Inc.). The optical density was measured at
405 nm (SPECTRAmax Plus 384, Molecular Devices, USA).
MAb 2D1 binding to rHA of pandemic H1N1 in a direct-binding
ELISA (at the same concentrations used for the competition
ELISA) was also carried out.
ii) Construction of yeast surface display vectors. A gene
fragment corresponding to amino acid residues 65–286 of HA1
from A/California/07/2009 (H1N1) (GenBank accession
ACP44189.1) with seven designed mutations was synthesized
(GenScript, NJ, USA) and cloned into the pPNLS yeast display
vector between the SfiI restriction-sites in-frame with the
endogenous yeast signal peptide and aga2 gene at the N-terminal
end and c-Myc tag at the C-terminal end [15]. This construct will
be referred to as pPNLS-H1pHA9. In the pPNLS-H1pHA9
background, four mutations were introduced to disrupt the Sa-
antigenic site of A/California/07/2009 (H1N1) HA. Alternatively,
the Sb-antigenic site of A/California/07/2009 (H1N1) HA was
disrupted by introducing six mutations [6,10]. These constructs
have been referred to as pPNLS-H1pHA9(Sa) and pPNLS-
H1pHA9(Sb), respectively. The sequences of all the constructs are
given in the Supplementary information.
iii) Yeast surface display of HA1 fragments and antibody
labeling experiments. The pPNLS yeast display plasmids
[pPNLS-H1pHA9, H1pHA9(Sa) and H1pHA9(Sb)] were trans-
formed into the yeast strain EBY100 using lithium acetate (LiAc)/
single-stranded DNA (SS-DNA) (LiAc/SS)-carrier DNA/PEG
method as described previously [16]. The display plasmid contains
a tryptophan marker gene (TRP1) that allows screening of the
transformed yeast on a selection media lacking tryptophan.
Expression of the HA1 proteins on the yeast cell surface was
performed as previously described [17]. Briefly, a single, well-
isolated, transformed colony was inoculated into 3 ml of synthetic
dextrose casamino acids (SDCAA) media (20 g/L dextrose, 6.7 g/
L Difco yeast nitrogen base, 5 g/L Bacto casamino acids, 14.7 g/
L sodium citrate, 4.29 g/L Citric acid; pH 4.5) and grown at 30uC
under shaking conditions until an OD600 of 2–3 was reached.
Yeast cells were then induced for protein display by transferring to
synthetic galactose casamino acids (SGCAA) medium (same as
SDCAA medium except 20 g/L galactose instead of dextrose) and
incubated with shaking at 20uC for 24 h.
After induction, a total of 16106 yeast cells were washed with
PBS containing 1% BSA (PBSB). Surface expression of the
displayed HA1 fragments was probed using anti-c-Myc chicken
antibody (Life technologies, NY, USA) at a pre-determined
dilution (1:300 in PBSB; 1 h, 4uC) directed towards the C-
terminal tag and subsequently stained with Alexa Fluor-488 goat
anti-chicken antibody (Life technologies) at a pre-determined
dilution (1:300 in PBSB; 1 h, 4uC, protected from light). The
conformational integrity of displayed protein was detected by
binding to MAb 2D1. 2D1-labeled yeast cells were subsequently
detected by staining with goat anti-human phycoerythrin (PE)
(Sigma Aldrich Inc.) at a pre-determined dilution (1:100 in PBSB;
1 h, 4uC). For binding specificity of surface-expressed HA1
fragments, the induced cells were incubated with different
concentrations of MA2077 (1 h, 4uC), and subsequently stained
with Alexa Fluor-633 rabbit anti-mouse antibody (Life technolo-
gies, NY, USA) at a pre-determined dilution (1:1500 in PBSB; 1 h,
4uC). After washing the stained cells with PBSB, fluorescence was
detected with a flow cytometer (BD FACS-Canto, BD Biosciences,
NJ, USA) and further analyzed with BD FACSDiva cytometry
software (BD Biosciences).
Results
Generation and characterization of MAbs against
pandemic H1N1
Employing the protocol as described in ‘Materials and Methods’,
14 MAbs were generated against pandemic H1N1 virus. Five
MAbs were of IgM isotype, 7 were of IgG1 isotype and 2 MAbs
were of IgG2a isotype. The ELISA reactivity profile of 6
representative MAbs is shown [Fig. 1]. In ELISA, 2 MAbs,
designated as MA2074 and MA2080 reacted with pandemic
H1N1 virus whereas MA2076 and MA2077, in addition also
reacted with rHA of pandemic H1N1 (A/California/04/2009)
[Fig. 1]. All these 4 MAbs failed to react with Vaxigrip (2009–10)
suggesting their specificity for pandemic H1N1 virus. Ten MAbs
also showed reactivity with Vaxigrip (2009–10) whereas none of
the MAbs reacted with rHA of seasonal H1N1 (A/Solomon
Islands/03/2006) and ovalbumin, used as negative control. The
Neutralizing Antibody against Pandemic H1N1 Virus
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culture supernatants of 2 MAbs (MA2076 and MA2077) reacting
with the pandemic H1N1 rHA were tested in a microneutraliza-
tion assay with homologous virus. One of the IgG1 isotype MAb,
MA2077, showed neutralization (,100%) of 100 TCID50 dose of
the pandemic H1N1 virus (data not shown). To obtain higher
amounts of the antibody, hybrid cell clone secreting MA2077 was
further grown as ascites and antibody was purified using Protein-
G. Purified MA2077 was again tested in ELISA and showed
significant binding upto 1 ng/ml with pandemic H1N1 virus as
well as pandemic H1N1 rHA (A/California/04/2009) protein and
failed to react with Vaxigrip (2009–10, Sanofi Pasteur) and
ovalbumin (Fig. 2).
Binding studies on Biacore
MAb MA2077 bound rHA (pandemic H1N1) A/California/
04/2009 with very high affinity and specificity. The equilibrium
dissociation constant (KD) of binding of MA2077 to pandemic HA
was 2.160.4 pM (Fig. 3, Table 1). There is minimal change in
response units (RU) during the dissociation phase probably
because of a very tight complex between the antibody-antigen
(MA2077-pandemic HA), hence, at best, we can determine
apparent off-rates [koff (1/s) = 9.27610
26]. MA2077 is specific to
the pandemic HA as the antibody did not show any detectable
binding to rHA (H1N1) A/Puerto Rico/8/34 (Table 1).
MAb MA2077 potently neutralizes pandemic H1N1 virus
Purified MA2077 was tested in an in vitro microneutralization
assay against 2009 pandemic H1N1 virus as well as seasonal
H1N1 (A/Solomon Islands/03/2006) virus. The IC50 and specific
activity values were calculated as described in Materials and Methods.
MA2077 showed potent neutralization of pandemic H1N1 virus
with an IC50 of 0.08 mg/ml. The specific activity of MA2077
against pandemic H1N1 virus was as low as 0.045 mg/ml (Table 2).
However, MA2077 failed to neutralize seasonal H1N1 virus (A/
Solomon Islands/03/2006) upto 25 mg/ml, the highest concen-
tration tested. To examine whether MA2077 inhibits the influenza
virus by blocking its attachment to the sialic acid receptor on the
host cell-surface, HI assay was performed using 1% guinea pig
RBCs and 4 HA units of the virus. MA2077 showed HI activity
against the pandemic H1N1 virus with specific activity of 0.50 mg/
ml, whereas it failed to show HI activity against seasonal H1N1
virus (A/Solomon Islands/03/2006) at concentrations upto
25 mg/ml (Table 2).
MAb MA2077 competes with MAb 2D1 for binding on
pandemic H1N1 HA
2D1, a previously reported MAb, isolated from a survivor of the
1918 Spanish flu binds within the ‘Sa’ antigenic site of 2009
Figure 1. ELISA reactivity profile of MAbs generated against pandemic H1N1. Culture supernatants of various hybrid cell clones generated
against pandemic H1N1 virus were tested in ELISA against pandemic H1N1 inactivated virus, Vaxigrip (2009–10) and ovalbumin as negative control
(200 ng/well). Additionally, plates coated with pandemic H1N1 A/California/04/2009 rHA protein (pHA) and seasonal H1N1 A/Solomon Islands/03/
2006) rHA protein (sHA) (160 ng/well) were also employed. Sera at a dilution of 1:500 from one of the mice immunized with the inactivated pandemic
H1N1 virus was used as positive control and Sp2/O culture supernatant was used as a negative control. Representative reactivity profiles of six MAbs
are shown. MAbs marked ‘‘#’’ are of IgM isotype, ‘‘*’’ IgG1 isotype and ‘‘@’’ IgG2a isotype, respectively.
doi:10.1371/journal.pone.0055516.g001
Figure 2. ELISA reactivity profile of MA2077. Purified MA2077 was
tested at varying concentrations in ELISA with pandemic H1N1
inactivated virus, Vaxigrip (2009–10 season, Sanofi Pasteur), ovalbumin
as negative control (200 ng/well) and mammalian expressed recombi-
nant pandemic H1N1 A/California/04/2009 HA protein (pHA; 160 ng/
well).
doi:10.1371/journal.pone.0055516.g002
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pandemic H1N1 HA [10]. Competition ELISA between MA2077
and 2D1 was done to determine, if the two antibodies bind to
sterically overlapping epitopes on pandemic H1N1 HA. The
concentration of MAb MA2077 used for competition was
determined from the titration curve with pandemic H1N1 rHA
(Fig. S1). In the presence of MA2077, binding of 2D1 to rHA of
pandemic H1N1 (A/California/04/2009) was significantly de-
creased when compared with the binding of 2D1 to rHA in the
absence of any competitor (MA2077). Concomitantly, with
decreasing 2D1 concentrations the binding of MA2077 to
pandemic H1N1 rHA increased (Fig. 4). This data suggests that
residues within the ‘Sa’ antigenic site may contribute to the
epitope of MA2077.
Design of head domain fragments of 2009 pandemic
H1N1 HA
An HA1 fragment, H1pHA9, defined by stable breakpoints in
the protein structure was designed in silico (Fig. 5A). Mutations
were introduced in the designed fragment to remove exposed
hydrophobic patches generated due to interactions lost with the
rest of HA, which could potentially cause protein aggregation. A
similar approach has been previously used by us to design stable
influenza and HIV-immunogens and inhibitors [18–20]. These
mutations were chosen based on accessibility calculations on a
homology model of A/California/07/2009 (H1N1) HA sequence
(GenBank accession ACP44189.1) using the structure of A/South
Carolina/1/1918 (H1N1) HA [PDB ID: 1RD8] as template which
was available when this study was initiated [21]. These calcula-
tions have been subsequently validated using the crystal structure
co-ordinates of A/California/04/2009 (H1N1) HA [PDB ID:
3LZG] which became available later [10]. Wild-type residue V97
mutated in our construct, is buried in the native A/California/04/
2009 (H1N1) HA structure, however we do not expect an iso-steric
substitution to Thr to considerably affect the folding of our
designed fragment. The mutated residues do not contribute to any
previously characterized antigenic sites or the receptor binding site
on HA. The mutations incorporated in H1pHA9 were A65S,
V97T, A232T, I233Q, V237T, I283R, I284T (Fig. 5B, Supple-
mentary Fig. S2). During the course of our work, design of similar
HA1-fragments has been reported [22,23]. However, none of the
previously reported designs had these additional engineered
mutations.
The antigenic sites ‘Sa’ or ‘Sb’ of pandemic H1N1 HA in our
designed fragment, H1pHA9, were independently mutated to
characterize the epitope of MAb MA2077. Residues in these
antigenic sites which had an accessibility of .20% were identified
and labeled ‘exposed’ [24]. Six residues (one in the Sa-epitope and
five in the Sb-epitope) within this ‘exposed’ set which were not
conserved between A/California/07/2009 (H1N1) HA (GenBank
accession ACP44189.1) and A/Puerto Rico/8/1934 (H1N1) HA
(GenBank accession ABD77675.1) were mutated with the wild-
type residue from the divergent PR-8 (H1N1) HA sequence. Two
other ‘exposed’ residues in the Sa-epitope were mutated to Ala and
S179 was mutated to Asn. In total, four mutations were introduced
in H1pHA9 to disrupt the Sa-epitope. The mutations incorporated
in H1pHA9(Sa) were N142A, N173A, S179N, K180N (Fig. 6A).
The Sb-epitope of H1pHA9 was disrupted by introducing six
mutations; T201N, A203K, D204E, Q206T, S207N, A212E
(Fig. 6B). The sequences of the various constructs are listed in
supplementary Fig. S2.
Epitope mapping by yeast cell-surface display
Here we describe a method to specifically detect if a given MAb
is targeted to the ‘Sa’ or ‘Sb’ antigenic sites of the pandemic H1N1
HA. All the HA1-fragments H1pHA9, H1pHA9(Sa) and
H1pHA9(Sb) were well expressed on the yeast cell surface, as
indicated by the fluorescence histograms for c-Myc labeling
(Fig. 7A–C). H1pHA9 displayed on yeast surface was properly
folded as assayed with MAb 2D1, which binds to a conformational
epitope on HA [10] (Fig. 7D). The yeast cells displaying HA1-
fragments were probed with different concentrations of MA2077.
The fluorescence histograms for MA2077 labeling suggests that
both H1pHA9 and H1pHA9(Sb) bind the neutralizing antibody
MA2077, with similar affinity (Fig. 8 A1–3, C1–3). However,
H1pHA9(Sa) has a drastically reduced affinity for MA2077, and at
the lowest concentration of MA2077 (62.5 nM) tested, there is
negligible binding (Fig. 8 B1–3).
Discussion
Considering the public health significance of the emergence of
new pathogens like pandemic H1N1, it is imperative to search for
newer diagnostic and therapeutic modalities to contain/alleviate
Figure 3. Biacore binding studies. 800 resonance units (RU) of
purified MAb MA2077 was immobilized on the surface of a CM5-chip.
As indicated, different concentrations of the pandemic H1N1 A/
California/04/2009 rHA trimer was passed over each channel. A channel
immobilized with ovalbumin served as negative control. MA2077 binds
to pandemic rHA with picomolar afiinity (KD = 2.160.4 pM). The kinetic
parameters were obtained by fitting the data to 1:1 Langmuir
interaction model using BIA EVALUATION 3.1 software. The dissociation
phase for two concentrations (4.25 nM and 3.0 nM) could not be fitted
since there was no measurable change in response units (RU). The data
points are in solid circles, while the fits are shown by solid lines. No
binding between rHA (H1N1) A/Puerto Rico/8/34 and MA2077 could be
detected (sensograms not shown).
doi:10.1371/journal.pone.0055516.g003
Table 1. Kinetic parameters for binding of MAb MA2077 to
rHA by surface plasmon resonance.
Analyte kon (1/Ms) koff (1/s) KD (M)
A/California/04/2009 HA (H1N1) 4.256106 9.2761026 2.1610212 60.4
A/Puerto Rico/8/34 HA (H1N1) -a -a -a
MA2077 was immobilized on the surface of a CM5-chip and analytes were
passed over this surface at different concentrations.
Reported values are the mean of kinetic parameters obtained at different
concentrations.
aNo detectable binding.
doi:10.1371/journal.pone.0055516.t001
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the disease progression. MAbs have been reported recently which
can broadly neutralize different influenza virus strains including
pandemic H1N1 [25,26]. In spite of this, there is scope to generate
a MAb with higher affinity, specificity and neutralizing ability that
could find utility in sensitive diagnostics and therapeutics due to
reduced dosage. The animal immune system has been naturally
designed for selection of high affinity full length MAbs as
compared to in vitro antibody generation approaches such as
phage display methods which result in scFv that is subsequently
converted to full length IgG. Generation of murine MAbs is also
cost effective. Hence, in this direction, we have generated murine
MAbs against the pandemic H1N1 virus. Two of the MAbs
specific to pandemic H1N1 virus also reacted with pandemic
H1N1 (A/California/04/2009) rHA protein. Some of the other
MAbs also showed reactivity with Vaxigrip (2009–10 Season,
Sanofi Pasteur) and thus it is possible that these antibodies either
recognized proteins other than HA, such as neuraminidase or
matrix protein of the pandemic H1N1 virus. The potential of such
MAbs in developing diagnostic tools for detection of pandemic
and seasonal influenza virus infection can be explored. One of the
MAb, MA2077 specifically recognized pandemic H1N1 (both
whole virus protein and HA protein) with significant reactivity
upto 1 ng/ml. MA2077 bound pandemic H1N1 rHA (A/
California/04/2009) with very high affinity (KD= 2.160.4 pM)
and specificity as determined by surface plasmon resonance.
Unlike MA2077, culture supernatant of the other MAb
(MA2076) reactive with the pandemic H1N1 rHA, failed to
neutralize the homologous virus (data not shown). It can be
speculated that MA2076 binds to non-neutralizing epitopes of the
HA protein. MA2077 neutralized pandemic H1N1 virus in an in
vitro microneutralization assay with an IC50 as low as 0.08 mg/ml.
Burioni et al., have reported pandemic H1N1 neutralizing MAbs
with IC50 in the range of 2.8–4 mg/ml [27]. Cabral et al., have also
been able to isolate neutralizing MAbs against pandemic H1N1
virus, with IC50 as low as 0.0025 mg/ml, wherein neutralization
capacity was assessed by employing plaque reduction assay instead
of microneutralization assay [28]. Hence, to the best of our
knowledge, MA2077, is a potent neutralizing MAb against
pandemic H1N1 virus, reported so far. Further, MA2077 also
showed HI activity against the pandemic H1N1 virus (Table 1).
This suggested that antibody mediates neutralization by binding to
the HA1 head region of the HA protein and blocking its
attachment with the sialic acid receptor. HI test is a routinely
used assay for identification of isolates of influenza viruses.
Therefore antibodies like MA2077 with high specificity may find
its application in influenza surveillance.
After establishing the ability of MA2077 to neutralize H1N1 by
binding to HA protein, the epitope recognized by it has been
elucidated by competition ELISA with a human monoclonal
antibody, 2D1. The MAb 2D1 isolated from a survivor of 1918
Spanish flu, binds to both 1918 as well as 2009 pandemic H1N1
viruses by recognizing the conserved ‘Sa’ antigenic site and has
reported specific activity of 0.04 mg/ml [9,10]. Competition results
showed that as the concentration of MAb 2D1 decreased, binding
of MA2077 to rHA increased (Fig. 4). This suggested that the two
antibodies might be binding to overlapping epitopes on pandemic
H1N1 HA.
Yeast cell-surface display is a convenient method for expression
and screening of combinatorial libraries of engineered proteins.
We have developed a methodology to rapidly characterize HA
head-domain specific antibodies using yeast cell-surface display of
HA1 fragments. A similar approach has been previously adopted
to characterize EGFR-specific antibodies [29]. The full length
protein (HA0) and its subunits (HA1 and HA2) from a highly
pathogenic H5N1 influenza virus have been previously displayed
on the yeast surface to map the antibody response against H5N1
HA [30]. In the present work, we designed a construct (H1pHA9)
encompassing the HA1 region corresponding to amino acid
residues 65–286 of A/California/07/2009 (H1N1) HA (GenBank
accession ACP44189.1). This construct (H1pHA9) was expressed
on the yeast cell surface. H1pHA9 showed good expression on the
Table 2. In vitro neutralization and HI activity of MA2077.
Virus strain Test IC50 value (mg/ml) Specific activity (mg/ml)
a
Pandemic H1N1 (A/California/07/2009) Neutralization assay 0.08 0.045
HI assay NA 0.50
Seasonal H1N1 (A/Solomon Islands/03/2006) Neutralization assay .25 .25
HI assay NA .25
aSpecific activity of MAb is the minimum concentration of the antibody required to neutralize 10% of 100 TCID50 dose of the virus in an in vitro microneutralization assay
or to inhibit 4 HA units of the virus in HI assay using 1% guinea pig RBCs.
.25 indicates that inhibitory activity was not detected at any concentration upto 25 mg/ml.
NA- Not applicable.
doi:10.1371/journal.pone.0055516.t002
Figure 4. Competition ELISA between MAb MA2077 and 2D1.
Microtiter plates were coated with pandemic H1N1 A/California/04/
2009 rHA (125 ng/well) and subsequently incubated with varying
concentrations of MAb 2D1. Competition ELISA was performed by
adding a fixed concentration of MA2077 (1 ng/ml) and plates were
processed as described in Materials and Methods. Values are expressed
as mean of the absorbance of duplicate readings obtained at 405 nm.
doi:10.1371/journal.pone.0055516.g004
Neutralizing Antibody against Pandemic H1N1 Virus
PLOS ONE | www.plosone.org 6 January 2013 | Volume 8 | Issue 1 | e55516
yeast cell surface, and bound well to two conformationally sensitive
MAbs, 2D1 and MA2077 (Fig. 7D, Fig. 8 A1–3). Though ‘Sa’ and
‘Sb’ sites are spatially in close proximity, simultaneous binding of
antibodies to these sites is not possible [6]. Hence, to demarcate
the involvement of either the ‘Sa’ or ‘Sb’ site in MA2077 binding,
mutations were independently introduced in both ‘Sa’ and ‘Sb’
sites of our construct H1pHA9 (Fig. 6A–B). The expression levels
of both H1pHA9(Sa) and H1pHA9(Sb) were comparable to that
of H1pHA9. However, MA2077 binding to H1pHA9(Sa)
displayed on yeast surface was completely abolished due to the
introduced mutations (Fig. 8 B1–3). However, binding to
H1pHA9(Sb) remained uncompromised (Fig. 8 C1–3). This data
further confirmed that the MA2077 binds within the ‘Sa’ antigenic
site. Interestingly, mouse MAbs have also been generated against
1918 Spanish flu virus-based vaccine, which neutralized the
pandemic H1N1 virus and its epitope has also been mapped to
‘Sa’ antigenic site [31].
Figure 5. Design of H1pHA9 fragment. An HA1 fragment, H1pHA9, defined by stable breakpoints was designed in silico. (A) Shown in stereoview
is the cartoon representation of H1N1 A/California/04/2009 HA trimer (PDB ID: 3LZG). Residues 65–286 comprising H1pHA9 (colored grey) have been
mapped onto a monomer (orange) of the crystal structure of H1N1 A/California/04/2009 HA. The rest of the molecule is colored green. The mutations
introduced in H1pHA9 are colored red. The receptor binding site residues are colored yellow. (B) The mutated residues (red) in H1pHA9 do not
contribute to any of the antigenic sites or the receptor binding site (yellow) on HA. The figures were generated in PyMOL (The PyMOL Molecular
Graphics System, version 1.2r2, DeLano Scientific, LLC).
doi:10.1371/journal.pone.0055516.g005
Figure 6. Design of H1pHA9(Sa) and H1pHA9(Sb) constructs. The ‘Sa’ and ‘Sb’ antigenic sites were independently mutated in our designed
fragment, H1pHA9. (A) ‘Sa’ antigenic site residues are colored cyan. The mutations introduced in H1pHA9(Sa) to disrupt this epitope are labeled
(colored blue). (B) ‘Sb’ antigenic site residues are colored light pink. The mutations introduced in H1pHA9(Sb) are labeled (colored pink). (A, B)
Mutations introduced in H1pHA9 to remove exposed hydrophobic patches are in red. The receptor binding site residues are in yellow. The figures
were generated in PyMOL (The PyMOL Molecular Graphics System, version 1.2r2, DeLano Scientific, LLC).
doi:10.1371/journal.pone.0055516.g006
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Figure 7. Expression of designedHA1 constructs on yeast cell surface. (A–C) Histograms depicting the fluorescence signal of Alexa Fluor-488 labeled
antibody bound to the C-terminal c-Myc tag of the displayed proteins. The Alexa Fluor-488 signal indicates the cell-surface expression of HA1 fragments. (D)
The designed fragment, H1pHA9, is well folded and bound the conformationally sensitive MAb 2D1 which was detected with PE-labeled antibody.
doi:10.1371/journal.pone.0055516.g007
Figure 8. Epitope mapping of MA2077 using yeast cell surface displayed HA1 fragments. Binding of the yeast cell surface displayed
H1pHA9 (A1–A3), H1pHA9(Sa) (B1–B3) and H1pHA9(Sb) (C1–C3) proteins to MA2077 was determined at different concentrations of antibody as
indicated. The bound MA2077 was stained with Alexa Fluor-633 labeled antibody. The fluorescence histograms suggest that H1pHA9 and
H1pHA9(Sb) bind MA2077 with similar affinity. (B1–3) Mutations in the Sa-antigenic site almost completely abolish binding to MA2077.
doi:10.1371/journal.pone.0055516.g008
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Acquisition of glycosylation at immunodominant sites is one of
the strategies adopted by influenza viruses to evade the host
immune response. Phylogenetic analyses have shown that the 1918
H1N1 virus (A/South Carolina/1/1918) lacked glycosylation near
the ‘Sa’ site and H1N1 influenza viruses from 1930–2007 have
gradually incorporated glycosylation at and around this site.
Interestingly, the 2009 pandemic H1N1 virus also lacks glycosyl-
ation at or near the ‘Sa’ antigenic site [10]. This may have
facilitated elicitation of antibodies recognizing the ‘Sa’ upon
immunization. Sequence comparison of variable regions of
MA2077 and 2D1 showed an identity of less than 25% (data
not shown). Further studies regarding the interaction of MA2077
with its epitope may reveal additional underlying mechanisms
employed by such antibodies binding to ‘Sa’ site to neutralize the
infectivity of the virus.
Due to its high affinity and specificity, MA2077 can be a
potential tool for sensitive diagnosis of pandemic H1N1 virus; for
studying the mechanistic details of antigen-antibody interactions in
context of neutralization of influenza virus and upon humaniza-
tion may be considered for therapeutic purposes. However, recent
reports have shown that under immune selection pressure, escape
mutants readily emerge for pandemic H1N1, and some of the
mutations lie in the ‘Sa’ region [32,33]. Hence, to take care of the
escape mutants, it will be imperative to use this antibody in
combination with other available MAbs for diagnosis of H1N1
influenza virus or as therapeutics. One of the unique merits of the
present study is that we have developed a yeast-display based
technique for rapidly identifying the putative epitope for head-
directed (Sa/Sb) antibodies using flow cytometry. This technique
can be further fine-tuned to obtain residue-specific information.
Supporting Information
Figure S1 Titration curve of MAbs MA2077 and 2D1
against pandemic H1N1 rHA by direct-binding ELISA.
Varying concentrations of MA2077 and 2D1 were tested against
mammalian cell expressed pandemic H1N1 A/California/04/
2007 rHA (125 ng/well) in direct binding ELISA. Values are
expressed as the mean of triplicate readings of absorbance at
405 nm.
(TIF)
Figure S2 Sequence of the designed HA1-fragments.
H1pHA9 corresponds to residues 65–286 of HA1 from A/
California/07/2009 (H1N1) (GenBank accession ACP44189.1)
with seven designed mutations to remove exposed hydrophobic
patches. The mutated residues are highlighted by bold alphabets.
Four additional mutations were made in H1pHA9(Sa) to disrupt
the ‘Sa’ antigenic site. These residues are underlined. The ‘Sb’
antigenic site was disrupted in H1pHA9(Sb) by six mutations in
H1pHA9. These residues are italicized. All the HA1-fragments
were cloned into the pPNLS yeast display vector between the SfiI
restriction-sites in-frame with the endogenous yeast signal peptide
and aga2 gene at the N-terminal end and c-Myc tag at the C-
terminal end.
(TIF)
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